Fluoxetine and motor recovery after ischaemic stroke

The Lancet Neurology

Volumn 10, Issue 6, 2011, Pages 499-

  Gaillard, Raphaël ^a,b   Mir, Olivier ^b  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; VASCULOTROPIN; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE; VASCULOTROPIN A;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BRAIN ISCHEMIA; DENTATE GYRUS; DEPRESSION; DRUG EFFICACY; GENE OVEREXPRESSION; HUMAN; LETTER; MOTOR CORTEX; MOTOR PERFORMANCE; NERVE EXCITABILITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOMOTOR DISORDER; SIGNAL TRANSDUCTION; ANIMAL; CONVALESCENCE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; STROKE; TREATMENT OUTCOME;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BRAIN ISCHEMIA; DRUG RESISTANCE; FLUOXETINE; HUMANS; MOTOR SKILLS; PLATELET AGGREGATION INHIBITORS; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; STROKE; TICLOPIDINE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79956038464     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70111-9     Document Type: Letter

References (11)

1. Chollet F, Tardy J, Albucher J-F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011, 10:123-130.
2. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009, 34:2459-2468.
3. Lee JS, Jang DJ, Lee N, et al. Induction of neuronal vascular endothelial growth factor expression by cAMP in the dentate gyrus of the hippocampus is required for antidepressant-like behaviors. J Neurosci 2009, 29:8493-8505.
4. Takebayashi M, Hashimoto R, Hisaoka K, Tsuchioka M, Kunugi H Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm 2010, 117:1119-1122.
5. Kubera M, Grygier B, Arteta B, et al. Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol Rep 2009, 61:1113-1126.
6. Sun Y, Jin K, Xie L, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003, 111:1843-1851.
7. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000, 106:829-838.
8. Lee SC, Lee KY, Kim YJ, Kim SH, Koh SH, Lee YJ Serum VEGF levels in acute ischaemic strokes are correlated with long-term prognosis. Eur J Neurol 2010, 17:45-51.
9. Boldrini M, Underwood MD, Hen R, et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009, 34:2376-2389.
10. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
11. Allaman I, Fiumelli H, Magistretti PJ, Martin JL Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl) 2011, published online Feb 8. 10.1007/s00213-011-2190-y.